Compounded semaglutide is a pharmacy-made version of the same active ingredient used in Ozempic and Wegovy. It is not FDA-approved — compounded drugs are not reviewed for safety, efficacy, or quality before they reach patients. Compounding is allowed only under specific legal conditions, and the FDA has warned about dosing errors, adverse reactions, and products that contain semaglutide salts not shown to be safe. Here is what the FDA, state pharmacy boards, and clinical data actually say.
What “Compounded” Means
Pharmacy compounding is the practice of combining, mixing, or altering ingredients to create a medication tailored to an individual patient — for example, changing a dosage, removing an allergen, or making a flavored liquid from a tablet. Two federal categories exist:
- 503A pharmacies compound for specific patients with a valid prescription. They are primarily regulated by state boards of pharmacy.
- 503B outsourcing facilities can make larger batches, register with the FDA, and must follow current good manufacturing practice (cGMP) standards.
Neither category submits products to the FDA for premarket review the way brand-name or generic drug manufacturers do. When a drug is in official shortage on the FDA’s shortage list, compounders can generally fill gaps; when a shortage is resolved, compounding of what are essentially copies of a commercially available FDA-approved product becomes more restricted.
How Compounded Semaglutide Compares to Ozempic and Wegovy
| Attribute | Ozempic / Wegovy (Novo Nordisk) | Compounded Semaglutide |
|---|---|---|
| FDA approval | Yes | No |
| Manufacturer quality oversight | Full cGMP | Varies by facility |
| Concentration standardization | Fixed per pen | Varies by pharmacy |
| Active ingredient form | Semaglutide (base) | Sometimes semaglutide salts |
| Clinical trial efficacy data | STEP, SUSTAIN, SELECT trials | None |
| Insurance coverage | Often covered | Usually cash-pay |
| Reporting of adverse events | Required MedWatch | Often inconsistent |
Safety Concerns the FDA Has Raised
The FDA’s consumer alert on semaglutide flags several issues:
- Dosing errors: Compounded vials are typically measured in units or milliliters using patient-supplied syringes; this has led to reports of tenfold overdoses and severe nausea, vomiting, and hospitalization.
- Salt forms: Some compounders have used semaglutide sodium or semaglutide acetate, which are not the same active ingredient used in FDA-approved products and have not been shown to be safe or effective.
- Source of active ingredient: Active pharmaceutical ingredient (API) imported from unverified facilities may not meet U.S. quality standards.
- Marketing claims: Some telehealth companies promote compounded semaglutide with language suggesting FDA approval; the FDA has sent warning letters.
Side Effects — What to Expect if the Product Is Genuine
If compounded semaglutide contains the correct active ingredient at the correct concentration, side effects should mirror those seen in semaglutide trials:
- Nausea, diarrhea, vomiting, constipation, and abdominal pain (most common)
- Headache, fatigue, and dyspepsia
- Rare but serious: pancreatitis, gallbladder disease, acute kidney injury, diabetic retinopathy worsening, serious allergic reaction
- Boxed warning for medullary thyroid carcinoma applies to any semaglutide product
Because concentrations and doses can vary between compounders, a change in pharmacy or batch can shift effectiveness or side-effect frequency even at the “same” prescribed dose.
How to Evaluate a Compounding Pharmacy
- Confirm state board of pharmacy licensure through your state board’s online lookup
- For bulk-batch products, confirm FDA 503B registration on the FDA’s outsourcing-facility list
- Check for recent FDA warning letters on the FDA website
- Ask for a certificate of analysis (COA) on the active ingredient
- Avoid pharmacies selling without a prescription or clinical evaluation
- Verify the clinician prescribing is licensed in your state
- Be skeptical of telehealth companies that guarantee approval, push high-volume refills, or refuse to discuss risks
- Report any adverse reactions to FDA MedWatch so regulators can track quality issues
Price alone is not a reliable signal. Compounded semaglutide is usually cheaper than brand-name products because it is not FDA-reviewed and is marketed as cash-pay through telehealth — but low cost can also reflect low-quality API or short-cutting on testing.
Where This Fits in a Broader Plan
Medications are only one lever. Lifestyle change — a prediabetes-friendly diet, physical activity, and sleep — remains first-line for prediabetes and weight management, and prediabetes is often reversible without injectables.
The Bottom Line
Compounded semaglutide is not FDA-approved, is not reviewed for safety, efficacy, or quality, and has been the subject of FDA warnings about dosing errors and non-approved salt forms. It may offer access when brand-name products are unavailable or unaffordable, but the trade-off is real. Work with a licensed clinician, verify any compounding pharmacy’s credentials, report adverse events, and make treatment decisions with a clear understanding of what is — and isn’t — in the vial.
This article is educational and does not replace personalized medical advice.
